DOCSLIB.ORG

Interferon-Gamma-Mediated Immunoevasive Stategies in Multiple Myeloma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interferon-Gamma-Mediated Immunoevasive Stategies in Multiple Myeloma INTERFERON-GAMMA-MEDIATED IMMUNOEVASIVE STATEGIES IN MULTIPLE MYELOMA DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Paul David Ciarlariello Graduate Program in Molecular Cellular and Developmental Biology The Ohio State University 2016 Dissertation Committee: Don M. Benson, Jr., MD, PhD -Advisor Michael A. Caligiuri, MD Gregory Lesinski, PhD Natarajan Muthusamy, DVM, PhD -Advisor Flavia Pichiorri, PhD Copyrighted by Paul David Ciarlariello 2016 Abstract Natural killer (NK) cells are a major source of interferon-γ (IFN-γ) and may play a key role in innate immunity against multiple myeloma (MM). IFN-γ abrogates MM tumor cell in vitro proliferation, however, clinical trials of recombinant IFN-γ in patients with MM showed no benefit. MM cells exhibit strategies designed to evade NK cell surveillance and lysis. Herein, we provide evidence of a novel means of MM immune evasion in which IFN-γ appears to play a reciprocal relationship between MM and NK cells. Patients with MM exhibit higher levels of serum IFN-γ levels than in the healthy setting. NK cells produce IFN-γ in response to MM cells which express functional IFN-γ receptors. Stimulation with IFN-γ leads to increased transcription and expression of the inhibitory ligands HLA-E and PD-L1 by MM cells. This effect may be overcome by interruption of the NKG2A / HLA-E interaction. Intriguingly, MM cells release extracellular vesicles (EV) which are capable of enhancing IFN-γ production of NK cell, thus describing a potential cyclic mechanism of perpetual immune detriment. Taken in total, these results suggest that MM cells subvert the favorable effects of IFN-γ to attenuate NK cell tumor-directed cytotoxicity. ii Dedication To my wife, Nicole, and my baby, Gianluca. To my parents, Paul and Sue. I am a scientist - I seek to understand me all of my impurities and evils yet unknown I am a scientist - I seek to understand me I am an incurable, and nothing else behaves like me I am a scientist- I seek to understand me [...] the hole I dig is bottomless, but nothing else will set me free -Guided By Voices iii Acknowledgments I would like to thank my advisor Dr. Don M. Benson, Jr. for taking the plunge and adopting me as his first and only graduate research student. Don, you have created a supporting environment in which I could grow as a scientist. If even an ounce of your knowledge, generosity, hospitality, and disposition have rubbed off on me, I will no doubt be a better researcher, father, and overall human being. Thank you, for lending your expertise and shepherding my training. I am forever grateful. Of course, I would like to acknowledge my co-mentor Dr. Raj Muthusamy for the many constructive conversations which kept me on track to graduate. Raj, curiosities pour out of you and I have had such a rewarding experience discussing my data and its implications. I will always admire your method and approach to properly designed and controlled experiments. A special thanks to Dr. Michael A. Caligiuri who brought me on to his team in 2007. Mike, you dispense positivity and influence with every word and action to those around you, and I am grateful for your support and guidance throughout the years. To Dr. Flavia Pichiorri, thank you for the many collaborative efforts and willingness to meet and discuss our mutual findings. I have enjoyed our colorful conversations and your constant excitement for decoding life’s secrets. To Dr. Greg Lesinski, thank you for your constructive and honest feedback throughout the years. I have always felt at ease in our exchanges, knowing that you were fully present and engaged in my scientific stories. iv I extend my endless respect and gratitude to my science “mommy”, Dr. Rossana Trotta. Rox, you make hypothesis-driven methods look deceivingly easy. I did not have a full appreciation of your expertise in experimental design until I was on my own. I think of you when considering experimental controls and especially when I am qualifying the conditions of my results. You have left such an impression on the scientist I have become. Thank you. I must honor and recognize my lab mate, Dr. Tiffany Hughes for her many supportive roles during my tenure. You have offered your help every day for the past six years and have asked nearly nothing in return. We as a lab were truly lucky to recruit you, and I am confident your many contributions will help rid the world of myeloma, once and for all. Some of the most rewarding experiences in the lab were moments while mentoring my undergraduates D. Maxwell Banaszak and Rohit Menon. I am glad to have been a part of your experience here at OSU. I know you both are ready to take on the world. My parents Paul and Sue Ciarlariello have selflessly supported me my entire life. Through their efforts, I have been afforded the free reign of pursuing my passions. Mom and Dad, I am without words as to how incredible my life experience has been. Let this accomplishment symbolize your success as parents. I have been and will always be proud to be your son. To my love, Nicole Danielle Ciarlariello. You are the most intuitive, thoughtful, and gentle soul I have ever come across and I am lucky to have you by my side. We now embark on new beginnings with our baby boy, Gianluca. I don’t care where we end up, as long as we are together. Thank you for believing in me, and trusting me with your heart. v Vita November 4, 1983 ............................................ Born, Dayton, Ohio June 2002 .......................................................... West Carrollton High School June 2006 .......................................................... B.S. Biochemistry, The Ohio State University September 2010 - Present ................................. Molecular, Cellular, and Developmental Biology Graduate School Program, The Ohio State University Publications Harshman, S. W., A. Canella, P. D. Ciarlariello, K. Agarwal, O. E. Branson, A. Rocci, H. Cordero, M. A. Phelps, E. M. Hade, J. A. Dubovsky, A. Palumbo, A. Rosko, J. C. Byrd, C. C. Hofmeister, D. M. Benson, Jr., M. E. Paulaitis, M. A. Freitas and F. Pichiorri (2016). "Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers." J Proteomics. Briercheck EL, R. Trotta ,L. Chen , A. S. Hartlage, J. P. Cole, T. D. Cole, C. Mao , P. P. Banerjee, H. T. Hsu , E. M. Mace, D. Ciarlariello, B. L. Mundy-Bosse, I. Garcia-Cao, S. D. Scoville, L. Yu, R. Pilarski, W. E. Carson, G. Leone, P. P. Pandolfi, J.Yu, J. S. Orange and M. A. Caligiuri (2015). “PTEN Is a Negative Regulator of NK Cell Cytolytic Function” J Immunol 194(4):1832-40. doi: 10.4049/jimmunol.1401224. Epub 2015 Jan 16. Collins, S. M., C. E. Bakan, G. D. Swartzel, C. C. Hofmeister, Y. A. Efebera, H. Kwon, G. C. Starling, D. Ciarlariello, S. Bhaskar, E. L. Briercheck, T. Hughes, J. Yu, A. Rice and D. M. Benson, Jr. (2013). "Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC." Cancer Immunol Immunother 62(12): 1841-1849. vi Harshman, S. W., A. Canella, P. D. Ciarlariello, A. Rocci, K. Agarwal, E. M. Smith, T. Talabere, Y. A. Efebera, C. C. Hofmeister, D. M. Benson, Jr., M. E. Paulaitis, M. A. Freitas and F. Pichiorri (2013). "Characterization of multiple myeloma vesicles by label-free relative quantitation." Proteomics 13(20): 3013-3029. Trotta, R., L. Chen, S. Costinean, S. Josyula, B. L. Mundy-Bosse, D. Ciarlariello, C. Mao, E. L. Briercheck, K. K. McConnell, A. Mishra, L. Yu, C. M. Croce and M. A. Caligiuri (2013). "Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells." Blood 121(16): 3126-3134. Trotta, R., L. Chen, D. Ciarlariello, S. Josyula, C. Mao, S. Costinean, L. Yu, J. P. Butchar, S. Tridandapani, C. M. Croce and M. A. Caligiuri (2012). "miR-155 regulates IFN-gamma production in natural killer cells." Blood 119(15): 3478-3485. Trotta, R., D. Ciarlariello, J. Dal Col, H. Mao, L. Chen, E. Briercheck, J. Yu, J. Zhang, D. Perrotti and M. A. Caligiuri (2011). "The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells." Blood 117(8): 2378-2384. Costinean, S., S. K. Sandhu, I. M. Pedersen, E. Tili, R. Trotta, D. Perrotti, D. Ciarlariello, P. Neviani, J. Harb, L. R. Kauffman, A. Shidham and C. M. Croce (2009). "Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice." Blood 114(7): 1374- 1382. Trotta, R., J. Dal Col, J. Yu, D. Ciarlariello, B. Thomas, X. Zhang, J. Allard, 2nd, M. Wei, H. Mao, J. C. Byrd, D. Perrotti and M. A. Caligiuri (2008). "TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells." J Immunol 181(6): 3784-3792. Trotta, R., D. Ciarlariello, J. Dal Col, J. Allard, 2nd, P. Neviani, R. Santhanam, H. Mao, B. Becknell, J. Yu, A. K. Ferketich, B. Thomas, A. Modi, B. W. Blaser, D. Perrotti and M. A. Caligiuri (2007). "The PP2A inhibitor SET regulates natural killer cell IFN-gamma production." J Exp Med 204(10): 2397-2405. Fields of Study Major Field: Molecular, Cellular, and Developmental Biology vii Table of Contents Abstract ..................................................................................................................................... ii Dedication.................................................................................................................................iii
Load more

Recommended publications
  • Induction of a TRAIL Mediated Suicide Program by Interferon Alpha in Primary E€Usion Lymphoma
    Oncogene (2001) 20, 7029 ± 7040 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Induction of a TRAIL mediated suicide program by interferon alpha in primary eusion lymphoma Ngoc L Toomey1,4, Vadim V Deyev2,4, Charles Wood3, Lawrence H Boise2, Duncan Scott1, Lei Hua Liu1, Lisa Cabral1, Eckhard R Podack2, Glen N Barber2 and William J Harrington Jr*,1 1Department of Medicine University of Miami School of Medicine, Miami, Florida, FL 33136, USA; 2Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, Florida, FL 33136, USA; 3School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, NE 68588, USA Gammaherpes viruses are often detected in lymphomas Virus (EBV) or Human Herpes Virus Type 8 (HHV-8) arising in immunocompromised patients. We have found have been isolated from lymphomas found in im- that Azidothymidine (AZT) alone induces apoptosis in munosuppressed organ transplant recipients, children Epstein Barr Virus (EBV) positive Burkitt's lymphoma with hereditary immunode®ciencies and patients with (BL) cells but requires interferon alpha (IFN-a) to induce acquired immunode®ciency (AIDS) (Swinnen, 1999; apoptosis in Human Herpes Virus Type 8 (HHV-8) Goldsby and Carroll, 1998; Knowles, 1999). Many of positive Primary Eusion Lymphomas (PEL). Our these tumors can be categorized into distinct subtypes analysis of a series of AIDS lymphomas revealed that based on a variety of morphologic and molecular IFN-a selectively induced very high levels of the Death criteria. For example, AIDS associated large cell Receptor (DR) tumor necrosis factor-related apoptosis- diuse or immunoblastic lymphomas (DLCL, IBL) inducing ligand (TRAIL) in HHV-8 positive PEL lines are often EBV positive while AIDS associated Burkitt's and primary tumor cells whereas little or no induction lymphomas (BL) less frequently contain EBV (Gaidano was observed in primary EBV+ AIDS lymphomas and et al., 1994).
    [Show full text]
  • Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection Against Classical Swine Fever Virus
    Article Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus Yusmel Sordo-Puga 1, Marisela Suárez-Pedroso 1 , Paula Naranjo-Valdéz 2, Danny Pérez-Pérez 1, Elaine Santana-Rodríguez 1, Talia Sardinas-Gonzalez 1, Mary Karla Mendez-Orta 1, Carlos A. Duarte-Cano 1, Mario Pablo Estrada-Garcia 1 and María Pilar Rodríguez-Moltó 1,* 1 Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba; [email protected] (Y.S.-P.); [email protected] (M.S.-P.); [email protected] (D.P.-P.); [email protected] (E.S.-R.); [email protected] (T.S.-G.); [email protected] (M.K.M.O.); [email protected] (C.A.D.); [email protected] (M.P.E.) 2 Central Laboratory Unit for Animal Health (ULCSA), Havana 11400, Cuba; [email protected] * Correspondence: [email protected]; Tel.: +53-7-2504419 Abstract: Live attenuated C-strain classical swine fever vaccines provide early onset protection. These vaccines confer effective protection against the disease at 5–7 days post-vaccination. It was previously reported that intramuscular administration of the Porvac® vaccine protects against highly virulent Citation: Sordo-Puga, Y.; classical swine fever virus (CSFV) “Margarita” strain as early as seven days post-vaccination. In Suárez-Pedroso, M.; Naranjo-Valdéz, order to identify how rapidly protection against CSFV is conferred after a single dose of the Porvac® P.; Pérez-Pérez, D.; subunit vaccine E2-CD154, 15 swine, vaccinated with a single dose of Porvac®, were challenged Santana-Rodríguez, E.; 3 intranasally at five, three, and one day post-vaccination with 2 × 10 LD50 of the highly pathogenic Sardinas-Gonzalez, T.; Mendez-Orta, Cuban “Margarita” strain of the classical swine fever virus.
    [Show full text]
  • Age- and Gender-Specific Modulation of Serum Osteopontin and Interferon-Α by Osteopontin Genotype in Systemic Lupus Er
    Genes and Immunity (2009) 10, 487–494 & 2009 Macmillan Publishers Limited All rights reserved 1466-4879/09 $32.00 www.nature.com/gene ORIGINAL ARTICLE Age- and gender-specific modulation of serum osteopontin and interferon-a by osteopontin genotype in systemic lupus erythematosus SN Kariuki1, JG Moore1, KA Kirou2,MKCrow2, TO Utset1 and TB Niewold1 1Section of Rheumatology, University of Chicago, Chicago, IL, USA and 2Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA Osteopontin (OPN) is a multifunctional cytokine involved in long bone remodeling and immune system signaling. Additionally, OPN is critical for interferon-a (IFN-a) production in murine plasmacytoid dendritic cells. We have previously shown that IFN-a is a heritable risk factor for systemic lupus erythematosus (SLE). Genetic variants of OPN have been associated with SLE susceptibility, and one study suggests that this association is particular to men. In this study, the 3 0 UTR SLE-risk variant of OPN (rs9138C) was associated with higher serum OPN and IFN-a in men (P ¼ 0.0062 and P ¼ 0.0087, respectively). In women, the association between rs9138 C and higher serum OPN and IFN-a was restricted to younger subjects, and risk allele carriers showed a strong age-related genetic effect of rs9138 genotype on both serum OPN and IFN-a (Po0.0001). In African- American subjects, the 5 0 region single nucleotide polymorphisms, rs11730582 and rs28357094, were associated with anti- RNP antibodies (odds ratio (OR) ¼ 2.9, P ¼ 0.0038 and OR ¼ 3.9, P ¼ 0.021, respectively). Thus, we demonstrate two distinct genetic influences of OPN on serum protein traits in SLE patients, which correspond to previously reported SLE-risk variants.
    [Show full text]
  • Interferon-Γ Enhances Interleukin 12 Production in Rheumatoid Synovial
    Interferon-γ Enhances Interleukin 12 Production in Rheumatoid Synovial Cells via CD40-CD154 Dependent and Independent Pathways MINETAKE KITAGAWA, HIROSHI SUZUKI, YOSHIHIRO ADACHI, HIROSHI NAKAMURA, SHINICHI YOSHINO, and TAKAYUKI SUMIDA ABSTRACT. Objective. To determine the role of interferon-γ (IFN-γ) in CD40-CD154 dependent production of interleukin 12 (IL-12) by synovial cells of patients with rheumatoid arthritis (RA). Methods. We examined the effects of IFN-γ, tumor necrosis factor-α (TNF-α), and granulocyte- macrophage colony stimulating factor (GM-CSF) on CD40 expression on CD68+ synovial macrophage-lineage cells (SMC). The effects of IFN-γ and soluble CD154 (sCD154) on IL-12 production by RA synovial cells were determined by ELISA. Results. CD68+ SMC expressed substantial levels of CD40. IFN-γ, but not TNF-α or GM-CSF, markedly upregulated CD40 expression on CD68+ SMC. IFN-γ also dose dependently increased IL- γ 12 production by synovial cells. The effects of IFN- on CD40 expression (EC50 = 127.4 U/ml) were observed at a concentration 19 times lower than the effects on IL-12 production (EC50 = 6.8 U/ml). Treatment with IFN-γ at a concentration low enough to augment CD40 expression but not IL-12 production enhanced spontaneous IL-12 production synergy with sCD154. The synergistic enhance- ment of spontaneous IL-12 production was abrogated by CD40-Fc. In contrast, IL-12 production induced by high concentration of IFN-γ was not neutralized by CD40-Fc. Conclusion. IFN-γ enhanced IL-12 production via both CD40-CD154 dependent and independent pathways in RA synovium. IFN-γ may play a crucial role in the development of RA synovitis through regulation of IL-12 production.
    [Show full text]
  • Dysregulated Interferon Response Underlying Severe COVID-19
    viruses Review Dysregulated Interferon Response Underlying Severe COVID-19 LeAnn Lopez y, Peter C. Sang y, Yun Tian y and Yongming Sang * Department of Agricultural and Environmental Sciences, College of Agriculture, Tennessee State University, 3500 John A. Merritt Boulevard, Nashville, TN 37209, USA; [email protected] (L.L.); [email protected] (P.C.S.); [email protected] (Y.T.) * Correspondence: [email protected]; Tel.: +1-615-963-5183 These authors contributed equally. y Academic Editor: Andrew Davidson Received: 27 October 2020; Accepted: 9 December 2020; Published: 13 December 2020 Abstract: Innate immune interferons (IFNs), including type I and III IFNs, constitute critical antiviral mechanisms. Recent studies reveal that IFN dysregulation is key to determine COVID-19 pathogenesis. Effective IFN stimulation or prophylactic administration of IFNs at the early stage prior to severe COVID-19 may elicit an autonomous antiviral state, restrict the virus infection, and prevent COVID-19 progression. Inborn genetic flaws and autoreactive antibodies that block IFN response have been significantly associated with about 14% of patients with life-threatening COVID-19 pneumonia. In most severe COVID-19 patients without genetic errors in IFN-relevant gene loci, IFN dysregulation is progressively worsened and associated with the situation of pro-inflammation and immunopathy, which is prone to autoimmunity. In addition, the high correlation of severe COVID-19 with seniority, males, and individuals with pre-existing comorbidities will be plausibly explained by the coincidence of IFN aberrance in these situations. Collectively, current studies call for a better understanding of the IFN response regarding the spatiotemporal determination and subtype-specificity against SARS-CoV-2 infections, which are warranted to devise IFN-related prophylactics and therapies.
    [Show full text]
  • An Overview on ERAP Roles in Infectious Diseases
    cells Review An Overview on ERAP Roles in Infectious Diseases 1,2, , 1, 2,3 1 Irma Saulle * y, Chiara Vicentini y, Mario Clerici and Mara Biasin 1 Cattedra di Immunologia, Dipartimento di Scienze Biomediche e Cliniche L. Sacco”, Università degli Studi di Milano, 20157 Milan, Italy; [email protected] (C.V.); [email protected] (M.B.) 2 Cattedra di Immunologia, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti Università degli Studi di Milano, 20122 Milan, Italy; [email protected] 3 IRCCS Fondazione Don Carlo Gnocchi, 20157 Milan, Italy * Correspondence: [email protected]; Tel.: +39-0250319679 These authors equally contributed to this work. y Received: 13 February 2020; Accepted: 12 March 2020; Published: 14 March 2020 Abstract: Endoplasmic reticulum (ER) aminopeptidases ERAP1 and ERAP2 (ERAPs) are crucial enzymes shaping the major histocompatibility complex I (MHC I) immunopeptidome. In the ER, these enzymes cooperate in trimming the N-terminal residues from precursors peptides, so as to generate optimal-length antigens to fit into the MHC class I groove. Alteration or loss of ERAPs function significantly modify the repertoire of antigens presented by MHC I molecules, severely affecting the activation of both NK and CD8+ T cells. It is, therefore, conceivable that variations affecting the presentation of pathogen-derived antigens might result in an inadequate immune response and onset of disease. After the first evidence showing that ERAP1-deficient mice are not able to control Toxoplasma gondii infection, a number of studies have demonstrated that ERAPs are control factors for several infectious organisms. In this review we describe how susceptibility, development, and progression of some infectious diseases may be affected by different ERAPs variants, whose mechanism of action could be exploited for the setting of specific therapeutic approaches.
    [Show full text]
  • Influence of ERAP1 and ERAP2 Gene Polymorphisms on Disease
    Human Immunology 80 (2019) 325–334 Contents lists available at ScienceDirect Human Immunology journal homepage: www.elsevier.com/locate/humimm Influence of ERAP1 and ERAP2 gene polymorphisms on disease T susceptibility in different populations ⁎ Yufeng Yaoa,b, Nannan Liua, Ziyun Zhoua, Li Shia,b, a Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, China b Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Disease, Kunming 650118, China ARTICLE INFO ABSTRACT Keywords: The endoplasmic reticulum aminopeptidases (ERAPs), ERAP1 and ERAP2, makes a role in shaping the HLA class ERAP1 I peptidome by trimming peptides to the optimal size in MHC-class I-mediated antigen presentation and edu- ERAP2 cating the immune system to differentiate between self-derived and foreign antigens. Association studies have Polymorphism shown that genetic variations in ERAP1 and ERAP2 genes increase susceptibility to autoimmune diseases, in- Disease association fectious diseases, and cancers. Both ERAP1 and ERAP2 genes exhibit diverse polymorphisms in different po- Population genetic background pulations, which may influence their susceptibly to the aforementioned diseases. In this article, we reviewthe distribution of ERAP1 and ERAP2 gene polymorphisms in various populations; discuss the risk or protective influence of these gene polymorphisms in autoimmune diseases, infectious diseases, and cancers; and highlight how ERAP genetic variations can influence disease associations. 1. ERAP gene introduction to CD8+ T cells [1,2]. ERAPs have been found to trim peptides to the optimal size for MHC-I binding [3,4] but can also over-trim and destroy 1.1. ERAPs play an important role in the antigen presentation process MHC-I ligands.
    [Show full text]
  • Pegasys, INN-Peginterferon Alfa-2A
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures, which have been finalised before 1 April 2005. For scientific information on procedures after this date please refer to module 8B. 1. Introduction Peginterferon alfa-2a is a polyethylene glycol (PEG)-modified form of human recombinant interferon alfa-2a intended for the treatment of adult patients with chronic hepatitis C (CHC) or chronic hepatitis B (CHB). Chronic hepatitis C is a major public health problem: hepatitis C virus (HCV) is responsible for a large proportion of chronic liver disease, accounting for 70% of cases of chronic hepatitis in industrialised countries. Globally there are an estimated 150 million chronic carriers of the virus, including 5 million in Western Europe. Without treatment approximately 30% of those infected with HCV will develop cirrhosis over a time frame of 30 years or more. For those with HCV-related cirrhosis, the prognosis is poor – a significant proportion will develop a life-threatening complication (either decompensated liver disease or an hepatocellular carcinoma) within a few years. The only therapy for those with advanced cirrhosis is liver transplantation, which carries a high mortality. In those who survive transplantation, viral recurrence in the new liver is almost inevitable and a significant proportion of infected liver grafts develop a progressive fibrosis that leads to recurrence of cirrhosis within 5 years. Interferon alfa monotherapy has been shown to be effective for the treatment of chronic hepatitis although sustained response rates occurred in approximately 15 to 30 % of patients treated for long duration (12-18 months). The current reference therapy is interferon alpha in combination with ribavirin, which resulted in an increase in biochemical and virological sustained response rates to approximately 40 % in naïve patients.
    [Show full text]
  • Induces Antigen Presentation in B Cells Cell-Activating Factor of The
    B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells This information is current as of September 27, 2021. Min Yang, Hidenori Hase, Diana Legarda-Addison, Leena Varughese, Brian Seed and Adrian T. Ting J Immunol 2005; 175:2814-2824; ; doi: 10.4049/jimmunol.175.5.2814 http://www.jimmunol.org/content/175/5/2814 Downloaded from References This article cites 54 articles, 36 of which you can access for free at: http://www.jimmunol.org/content/175/5/2814.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 Min Yang,* Hidenori Hase,* Diana Legarda-Addison,* Leena Varughese,* Brian Seed,† and Adrian T.
    [Show full text]
  • Antigen-Specific Induced Foxp3 Regulatory T Cells Are Generated
    Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade Ivana R. Ferrer, Maylene E. Wagener, Minqing Song, Allan D. Kirk, Christian P. Larsen, and Mandy L. Ford1 Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA 30322 Edited by James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, and approved November 4, 2011 (received for review April 7, 2011) Blockade of the CD40/CD154 pathway potently attenuates T-cell in vivo accumulation of Treg and deletion of graft-specific ef- responses in models of autoimmunity, inflammation, and trans- fectors after CD40/CD154 blockade has not been investigated. plantation. Indeed, CD40 pathway blockade remains one of the To address these questions, we used an ovalbumin (OVA)- most powerful methods of prolonging graft survival in models of expressing transgenic mouse model (20), which allowed us to di- + + transplantation. But despite this effectiveness, the cellular and rectly track both donor-reactive CD4 and CD8 T-cell responses molecular mechanisms underlying the protective effects of CD40 simultaneously over time. Although previous studies have used pathway blockade are incompletely understood. Furthermore, the transgenic models to assess the degree of T-cell deletion after CD154/CD40 blockade (16, 21), none has systematically inter- relative contributions of deletion, anergy, and regulation have not + been measured in a model in which donor-reactive CD4+ and CD8+ rogated the impact of anti-CD154 on the kinetics of both CD4 and CD8+ T-cell deletion and acquisition of effector function. T-cell responses can be assessed simultaneously. To investigate the fi Our results indicated that although CD40/CD154 blockade alone impact of CD40/CD154 pathway blockade on graft-speci c T-cell delayed donor-reactive CD4+ and CD8+ T-cell expansion and responses, a transgenic mouse model was used in which recipients differentiation, the addition of DST was required for antigen- fi + + containing ovalbumin-speci cCD4 and CD8 TCR transgenic T specific T-cell deletion.
    [Show full text]
  • Interferon Gamma Release Assay (IGRA) Interferon Gamma Release Assay (IGRA) Is a Blood Test That Has Recently Been Introduced As Another Method to Diagnose LTBI
    Section 4: TB Screening These cases also included patients that did not have previous exposure to tuberculin. It is imperative that health care providers should have Epinephrine Hypochloride solution (1:1000) and other appropriate agents available for immediate use in the case of a hypersensitivity reaction. As per NACI, recommendations all patients must be monitored for 15 minutes after inoculation. Interferon Gamma Release Assay (IGRA) Interferon gamma release assay (IGRA) is a blood test that has recently been introduced as another method to diagnose LTBI. Therefore, it can complement the TST in certain situations. In general, IGRAs are more specific than the TST in populations vaccinated with BCG, especially if BCG is given after infancy or multiple times. When a person is exposed to MTB it produces many immune cells, which produce various proteins. Among these proteins are interferon gamma or IFN-y. The interferon gamma release assay (IGRA) is a blood test that measures IFN-y. Therefore, if a person has been exposed and infected with TB, IFN-y can be detected with this test. There are two IGRA tests used in Canada, the T-SPOT.TB test and the QuantiFERON®-TB Gold test. Provincial Laboratory (ProvLab) Alberta uses QuantiFERON®-TB Gold (QFT) test in the NWT. Specimens must be received by the regional laboratory and incubated for 16–24 hours. This limits availability of this test in the NWT. IGRA can only be ordered through the Office of the Chief Public Health Officer and Stanton Regional Hospital Specialists who are involved in TB management and treatment. IGRAs require laboratories with adequate equipment and trained personnel to perform the assays.
    [Show full text]
  • Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
    Review Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation Leonor S. Castro 1,†, Guilherme S. Lobo 1,†, Patrícia Pereira 2 , Mara G. Freire 1 ,Márcia C. Neves 1,* and Augusto Q. Pedro 1,* 1 CICECO–Aveiro Institute of Materials, Chemistry Department, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; [email protected] (L.S.C.); [email protected] (G.S.L.); [email protected] (M.G.F.) 2 Centre for Mechanical Engineering, Materials and Processes, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Polo II, 3030-790 Coimbra, Portugal; [email protected] * Correspondence: [email protected] (M.C.N.); [email protected] (A.Q.P.) † These authors contributed equally to this work. Abstract: The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and their derivatives accounting for most of the generated revenues. The success of pharmaceutical biotechnology is closely linked with remarkable developments in DNA recombinant technology, which has enabled the production of proteins with high specificity. Among promising biopharmaceuticals are interferons, first described by Isaacs and Lindenmann in 1957 and approved for clinical use in humans nearly thirty years later. Interferons are secreted autocrine and paracrine proteins, which by regulating several biochemical Citation: Castro, L.S.; Lobo, G.S.; pathways have a spectrum of clinical effectiveness against viral infections, malignant diseases, Pereira, P.; Freire, M.G.; Neves, M.C.; and multiple sclerosis.
    [Show full text]